Linaclotide (Linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation

P and T

Volumn 38, Issue 3, 2013, Pages 154-160

  Thomas, Rachel Hutchins ^a   Allmond, Kyle ^b  

^a SAMFORD UNIVERSITY   (United States)

^b Caspi and Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINACLOTIDE; LUBIPROSTONE; PLACEBO; TEGASEROD;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; CHEST TIGHTNESS; CONSTIPATION; DIARRHEA; DRUG COST; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FLATULENCE; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT;

EID: 84875201523     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480-1491; erratum, 2006;131(2):688.
2. Spiller R, Aziz Q, Creed F, et al. Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: Mechanisms and practical management. Gut 2007;56(12):1770-1798; erratum, 2008;57(12):1743.
3. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. American College of Gastroenterology Task Force on Irritable Bowel Syndrome: An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104:S1-S35.
4. Higgins PD, Johanson JF. Epidemiology of constipation in North America: A systematic review. Am J Gastroenterol 2004;99:750-751.
5. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: Systematic review and meta-analysis. Gut 2011;60(2):209-218.
6. Amitiza (lubiprostone) capsules, prescribing information. Deerfield, Ill: Takeda; November 2012. Available at: http://amitizahcp.com/default.aspx. Accessed December 12, 2012.
7. Thomson Reuters Drugdex. Lubiprostone. Available at: www.thomsonhc.com. Accessed December 12, 2012.
8. Ambizas EM, Ginzburg R. Lubiprostone: A chloride channel activator for treatment of chronic constipation. Ann Pharmacother 2007;41(6):957-964.
9. Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Exp Opin Drug Saf 2012; 11(5):841-850.
10. Lembo AJ, Johanson JF, Parkman HP, et al. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 2011;56(9):2639-2645.
11. Elsevier Gold Standard Clinical Pharmacology Online. Tegaserod. Available at: http://clinicalpharmacology.com. Accessed December 12, 2012.
12. FDA announces discontinued marketing of GI drug, Zelnorm, for safety reasons. March 30, 2007. Available at: www.fda. gov/NewsEvents/Newsroom/Press Announcements/2007/ucm108879.htm. Accessed September 19, 2012.
13. FDA permits restricted use of Zelnorm for qualifying patients. July 27, 2007. Available at: www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2007/ ucm108956.htm. Accessed September 19, 2012.
14. Zelnorm (tegaserod maleate) information. Available at: www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafety-InformationforPatientsandProviders/ ucm103223.htm. Accessed September 19, 2012.
15. FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation, August 30, 2012. Available at: www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm317505.htm#. Accessed September 20, 2012.
16. Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell 1990;63(5):941-948.
17. Bharucha AE, Linden DR. Linaclotide: A secretagogue and antihyperalgesic agent. What next? Neurogastroenterol Motil 2010;22(3):227-231.
18. Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010;649(1-3):328-335.
19. Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther 2011;130(1):71-82.
20. Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22(3):312-e84.
21. Linzess (linaclotide) capsules, prescribing information. Cambridge, Mass.: Ironwood Pharmaceuticals; August 2012. Available at: www.frx.com/pi/linzess_pi.pdf. Accessed December 12, 2012.
22. Busby RW, Kessler MM, Bartolini WP, et al. Pharmacological properties, metabolism and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 2013; 344(1):196-206.
23. Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010;86(19-20):760-765.
24. Kurtz C, Fitch D, Busby RW, et al. Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects (Abstract 132). Gastroenterology 2006;130:A26.
25. Currie MG, Kurtz C, Mahajan-Miklos S, et al. Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects (Abstract 894). Am J Gastroenterol 2005;100:S328.
26. O'Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990;300(6722):439-440.
27. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107(11):1702-1712.
28. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107(11):1714-1724.
29. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365(6):527-536.
30. FDA, Center for Drug Evaluation and Research. Guidance for Industry: Irritable Bowel Syndrome. Clinical Evaluation of Drugs for Treatment. May 2012. Available at: www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatory-Information/Guidances/UCM205269.pdf. Accessed December 10, 2012.
31. FDA, Center for Drug Evaluation and Research. Application No. 202811 Orig1s000. Summary Review. August 29, 2012. Available at: www. accessdata.fda.gov/drugsatfda_docs/ nda/2012/202811Orig1s000SumR.pdf. Accessed December 10, 2012.
32. Red Book Online. Linaclotide. Ann Arbor, Mich.: Truven Health Analytics. Available at: www.truvenhealth.com. Accessed February 8, 2013.
33. Red Book Online. Lubiprostone. Ann Arbor, Mich.: Truven Health Analytics. Available at: www.truvenhealth.com. Accessed February 8, 2013.